Aerobic vs Resistance Exercise in Post-menopausal Women With Type 1 Diabetes
NCT ID: NCT05188027
Last Updated: 2025-02-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
20 participants
INTERVENTIONAL
2021-11-16
2025-12-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effects of Resistance Exercise on Blood Glucose in Post-menopausal Women With Type 1 Diabetes
NCT05203640
Exercise and the Menstrual Cycle in Type 1 Diabetes
NCT05188014
The Influence of Different At-home Exercise Strategies on 24h Glycemic Control
NCT05490706
Aerobic and Strength Training With Caloric Restriction on Insulin Resistance in Obese Premenopausal Women
NCT03716336
Effectiveness of Aerobic Exercise to Mitigate Hyperglycemia After Fasted Resistance Exercise
NCT05203653
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Testing sessions: Participants will be asked to arrive at the lab at around 4:00 pm for all three sessions, which will be randomly assigned. During the sessions, participants will be asked to perform one of the three activities: 1) seated rest 2) aerobic exercise (walking on a treadmill at 50% of the participant's pre-determined VO2max) or 3) resistance exercise consisting of 1 set of 10 repetitions of 10 different exercises with 90 seconds rest between sets. Blood samples will be drawn at baseline, after 10, 20 and 30 minutes of exercise, along with 30- and 60-minutes post-exercise via an IV catheter. Indirect calorimetry will be used to ensure that the participant is exercising at the appropriate intensity. Participants will be asked to match their daily food and insulin intake as closely as possible from one testing session to the next for the day before, day of and day after the testing session. The investigators will provide them with log sheets to assist in this task. They will also be asked to avoid strenuous exercise and alcohol intake.
A CGM sensor will be subcutaneously inserted by one of the investigators (trained by a group from the CGM manufacturer) into the anterior abdominal area of the participant, or on the back of the arm of the participant, approximately 2 days prior to the first testing session. The Dexcom G6 CGM receiver will store glucose data every 5 minutes for up to 10 days. The participant will be instructed on how to remove their sensor at least 24 hours after the exercise session, and will be asked to return the receiver to enable the upload of their data to Dexcom Clarity by the study team.
Interviews: During the third and final testing session, study participants will be invited to answer questions about their study participation experience, exercise preferences, barriers to exercise, and other information they feel may improve their exercise experience. These interviews will be audio recorded and transcribed.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
All participants
All participants will take part in all three testing conditions
Aerobic Exercise
Walking at 60% of maximal aerobic capacity on a treadmill
Resistance Exercise
Performing one set of 10 repetitions of 10 different weight-lifting exercises
No exercise
Participants will rest in a supine position for 30 minutes.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Aerobic Exercise
Walking at 60% of maximal aerobic capacity on a treadmill
Resistance Exercise
Performing one set of 10 repetitions of 10 different weight-lifting exercises
No exercise
Participants will rest in a supine position for 30 minutes.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* post-menopause (at least one year since last menstrual period), or have had a hysterectomy and bilateral salpingo oophorectomy
* able to perform aerobic and resistance exercise
* able to visit the lab in Edmonton, Alberta (University of Alberta)
Exclusion Criteria
* frequent and unpredictable hypoglycemia
* change in insulin management strategy within the last 2 months
* blood pressure \> 140 / 95
* severe peripheral neuropathy
* history of cardiovascular disease
* musculoskeletal injuries interfering with exercise performance
* use of medications (other than insulin) that affect glucose metabolism
* BMI \> 30 kg/m2
* smoking
* moderate to high alcohol intake (\> 2 drinks/day)
45 Years
75 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Women and Children's Health Research Institute, Canada
OTHER
University of Alberta
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Alberta Diabetes Institute
Edmonton, Alberta, Canada
Institut de recherches cliniques de Montréal
Montreal, Quebec, Canada
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Pro00107673
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.